ReviewCureus2026
Comparative Efficacy of Interleukin Inhibitors and JAK Inhibitors in Moderate to Severe Plaque Psoriasis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plaque psoriasis is a chronic autoimmune skin condition characterized by erythematous, scaly plaques that commonly affect the scalp, trunk, and extensor surfaces. As the most prevalent form of psoriasis, it results from immune system dysregulation, particularly involving cytokines. Cytokines such as interleukin-17 (IL-17) and interleukin-23 (IL-23), as well as downstream Janus kinase (JAK)/tyrosine kinase 2 (TYK2) signal pathways, lead to accelerated skin cell turnover. While an expanding array of treatment options exists, including topical agents, conventional oral medications, and targeted biologics, gaps persist in optimizing long-term management, such as improving access to medications and balancing efficacy with patient preference. Effective, practical, and acceptable long-term treatment options are needed. Injectable interleukin inhibitors, such as risankizumab (Skyrizi
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.